The V3 Domain of SIVmac251 gp120 Contains a Linear Neutralizing Epitope  by Palker, Thomas J. et al.
VIROLOGY 224, 415–426 (1996)
ARTICLE NO. 0548
The V3 Domain of SIVmac251 gp120 Contains a Linear Neutralizing Epitope
THOMAS J. PALKER,1 ANDREW J. MUIR, DERRY E. SPRAGION, HERMAN F. STAATS,
ALPHONSE LANGLOIS,* and DAVID C. MONTEFIORI*
Departments of Medicine and *Surgery, Duke University Medical Center, Durham, North Carolina 27710
Received May 9, 1996; accepted August 5, 1996
Antisera to 21 synthetic peptides containing hydrophilic sequences of simian immunodeficiency virus strain mac251
(SIVmac251) gp120 and gp32 were tested for the ability to neutralize SIVmac251. Goat antisera raised to peptides SP-1
and SP-1V containing the carboxy-terminal portion of the V3 domain of SIVmac251 gp120 between amino acids 327 and
339 inhibited syncytium formation (90% inhibition at a 1/1024 dilution) and cell killing of CEMx174 cells by SIVmac251 (50%
inhibition of cell killing at a dilution of 1/5832), SIVDeltaB670 (1/568), and SIVsmH4 (1/740). Neutralizing antibodies to
SIVmac251, SIVDeltaB670, and SIVsmH4 could be adsorbed by peptides containing a neutralizing V3 sequence of SIVmac251
gp120 (GLVFHSQPIND, amino acids 329–339) but not by peptides lacking this sequence. This V3 neutralizing region
corresponds to a homologous V3 neutralizing site within HIV-2 gp120 reported by Bjo¨rling et al. 1991, Proc. Natl. Acad. Sci.
USA 88, 6082–6086, 1994, J. Immunol. 152, 1952–1959). Antibodies in 20 of 31 sera obtained from rhesus macaques
infected with SIVmac251 reacted with a peptide containing the entire V3 sequence of SIVmac251 gp120, whereas no sera
contained antibodies reacting with the V3 neutralizing site between amino acids 329 and 339. Low levels of antibody-
mediated recognition and subsequent lack of selective pressure against this linear V3 neutralizing site might in part explain
why this region is not a dominant neutralizing site and also why sequences within V3 do not vary during the course of SIV
infection. q 1996 Academic Press, Inc.
INTRODUCTION ties among the envelope glycoproteins of HIV-1, HIV-2,
and SIV. The envelope genes of HIV-1, HIV-2, and SIV
Human immunodeficiency virus types 1 and 2 are len- (Veronese et al., 1989) encode polyprotein precursors
tiviruses that are etiologically linked to AIDS (Barre´-Si- that, upon proteolytic processing, give rise to gp120 ex-
noussi et al., 1983; Levy et al., 1984). Simian immunodefi- ternal envelope glycoprotein and gp41/32 transmem-
ciency viruses (SIV) are nonhuman primate lentiviruses brane glycoproteins. The envelope glycoproteins of HIV-1
with biological characteristics and genomic organization and SIV have 40% amino acid sequence identity, whereas
similar to both HIV-1 and HIV-2 (Daniel et al., 1985; Letvin HIV-2 and SIV are approximately 75% identical (Chakra-
et al., 1985; Murphey-Corb et al., 1986; Chakrabarti et al., barti et al., 1987; Franchini et al., 1987; Hirsch et al., 1989;
1987; Franchini et al., 1987; Hirsch et al., 1989). Infection Myers et al., 1993). Based on the nonrandom clusters
of rhesus monkeys with some SIVs results in an AIDS- of sequence changes found in various HIV-1 and HIV-2
like disease characterized by destruction of CD4/ T- isolates, it is possible to divide the amino acid sequences
cells and the onset of opportunistic infections (Daniel et of HIV-1 and HIV-2 gp120 into five constant and variable
al., 1985; Letvin et al., 1985; Murphey-Corb et al., 1986). (V) domains (Myers et al., 1992). While SIV gp120 also
Strains of HIV-2 have the closest genetic similarity to has V1, V2, V4, and V5 regions homologous to those
SIVs infecting rhesus macaques (SIVmac) and sooty found in HIV-1 and HIV-2 gp120, the putative V3 domain
mangabeys (SIVsm) (Kornfeld et al., 1987; Gardner and does not vary during the course of SIV infection (Burns
Luciw, 1988; Hirsch et al., 1989; Gao et al., 1992). Com- and Desrosiers, 1991; Johnson et al., 1991; Overbaugh
parison of nucleotide sequences within the pol and env et al., 1991; Almond et al., 1992). However, for both SIV
genes and the long terminal repeat regions of HIV-2 indi- and HIV-1, amino acid changes within V3 are associated
cates that HIV-2, SIVmac, and SIVsm can be grouped with altered cell and tissue tropism (Shioda et al., 1991;
together phylogenetically even though they are isolated Cann et al., 1992; Hwang et al., 1992; Kodama et al.,
from different species (Chakrabarti et al., 1987; Franchini 1993; Campbell and Hirsch, 1994; Hirsch et al., 1994;
et al., 1987; Hirsch et al., 1989; Gao et al., 1992). Kirchhoff et al., 1994). The V3 domain of HIV-1 gp120 is
There are substantial functional and structural similari- bounded by cross-linked cysteines and contains domi-
nant type-specific neutralizing sites (Palker et al., 1988;
Rusche et al., 1988; Goudsmit et al., 1988, Kinney-1 To whom reprint requests should be addressed at Box 3307, Duke
University Medical Center, Durham, NC 27710. Fax: (919) 684-4288. Thomas et al., 1988). Similarly, Bjo¨rling et al. (1991, 1994)
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have reported two linear neutralizing sites within and the peptide. Peptides used for adsorption of antisera
were estimated to be at least 75% pure by HPLC.adjacent to the C-terminus of the V3 region of HIV-2
gp120.
Antisera and antibodiesDespite antigenic similarities of gp120 from SIVmac/
sm and HIV-2 (Robert-Guroff et al., 1992) as well as the
Synthetic peptides with reduced cysteines were cova-
identification of linear neutralizing sites within V3 of HIV-
lently linked to either tetanus toxoid (kindly provided by
2 gp120 (Bjo¨rling et al., 1991, 1994) and the phylogenetic
Dr. Frank McCarthy, Wyeth Laboratories) or keyhole lim-
grouping of SIVmac/sm with HIV-2 (Chakrabarti et al.,
pet hemocyanin (KLH; Calbiochem, San Diego, CA) at a
1987; Franchini et al., 1987; Hirsch et al., 1989), it has
molar ratio of at least 30:1 (peptide to carrier protein)
not been possible to demonstrate that the V3 domain of
with m-maleimidobenzoyl-N-hydroxysuccinimide ester
gp120 from SIVmac strain 251 contains a linear neutraliz-
(Sigma Chemical Co., St. Louis, MO) as previously de-
ing site (Robert-Guroff et al., 1992; Javaherian et al., 1992).
scribed (Green et al., 1982). Goats (N  36) were immu-
Previous studies have shown that, in contrast to the lin-
nized with peptide conjugates (5 mg) emulsified in com-
ear neutralizing sites within HIV-1 V3, the principal neu-
plete (Day 0) and incomplete (Days 7, 14, and 28)
tralizing determinant (PND) of SIVmac251 is conforma-
Freund’s adjuvants injected subcutaneously in four quad-
tional (Haigwood et al., 1992; Javaherian et al., 1992,
rilateral dorsal sites. Additional booster immunizations
1994). Here we provide corroborative data regarding the
every 2 weeks for 2–4 months were also administered
conformational nature of the PND of SIVmac251 but also
if anti-peptide antibody titers were less than 1/1000 in
report confirmation in three independent laboratories
ELISA. Guinea pigs (N  12) were also immunized sc
(T.P., A.L., D.M.) that anti-peptide antisera raised to a
with peptide (SP-1, 1V, and SP-16)–KLH conjugates in
linear determinant within the C-terminal region of SIVmac
Freund’s complete and incomplete adjuvants or with cy-
gp120 V3 can neutralize SIVmac251 as well as related
clized peptide SP-4 for production of antisera at Hazelton
viruses.
Research Products, Inc. (Denver, PA). Additional antisera
were raised to DP-314–KLH in C57BL/6 mice (N  6)
either by intranasal administration of 50 mg of peptideMATERIALS AND METHODS
conjugate with cholera toxin on Days 0, 7, 14, and 28
Peptides (Staats et al., 1996) or by sc immunization with complete
(Day 0) and incomplete (Days 7, 14, and 28) Freund’s
Deduced amino acid sequences of SIVmac251 enve-
adjuvants as previously described (Palker et al., 1992).
lope glycoproteins are from Franchini et al. (1987) and
Preimmune and immune sera collected 7–10 days after
the Los Alamos database (Myers et al., 1992). Within
booster immunizations were stored at 0707 until use.
the putative V3 domain, reported sequences from these
Sera from 31 macaques experimentally infected with
sources differ in two envelope amino acids (aa 337, 338);
SIVmac251 were provided by Dr. Norman Letvin, Beth
thus, V3 peptides SP-1 and SP-1V were synthesized con-
Israel Hospital and Harvard University. Polyclonal antise-
taining sequences from Franchini et al. (1987) and the
rum to recombinant gp120 from the SIV molecular clone
Los Alamos database (Myers et al., 1993), respectively
1A11 was provided by Drs. P. Luciw, University of Califor-
(Table 1). Hydrophilic amino acid sequences of SIV-
nia (Davis, CA) and K. Steimer, Chiron Corp. (Emeryville,
mac251 envelope were identified by computer analysis
CA). Monoclonal antibodies (mab) KK8, KK45, KK46, and
using the method of Kyte and Doolittle (1982). Peptides
KK65 to SIVmac251 gp120 (Kent et al., 1991, 1992) as
SP-1, 1V, 2-7, 17, 18, and V5 as well as peptides with the
well as SIVmac239 gp130 and HIV-1IIIB/LAI gp120 were
prefix DP were synthesized at the Duke University Center
obtained from the NIH AIDS Research and Reference
for AIDS Research Peptide Synthesis Core Facility on an
Reagent Program operated by McKesson BioServices
Applied Biosystems, Inc. (ABI) 431A peptide synthesizer
Corp. (Rockville, MD). Monoclonal antibodies to HIV-2
using T-boc or F-moc protecting groups. Peptides SP-8 to
gp120 were provided by Dr. James Hoxie, University of
SP-16 were synthesized at the Howard Hughes Medical
Pennsylvania (Philadelphia, PA).
Institute Durham Biopolymer Laboratory on an ABI 431A
peptide synthesizer using F-moc protecting groups. Pep- Viruses and cell lines
tides RG-1 and RG-2 and alanine-substituted peptides
A1–A11 in which each amino acid within the V3 se- The HuT-78 and CEMx174 human T-cell lines were
obtained from Dr. Barton Haynes, Duke University Medi-quence GLVFHSQPIND (aa 329–339) was sequentially
replaced with alanine were synthesized at Research Ge- cal Center and Dr. James Hoxie, University of Pennsylva-
nia, respectively. Cells were grown at 377 in a humidifiednetics, Inc. (Huntsville, AL). Peptides coupled to carrier
proteins and used for immunization were evaluated by chamber containing 5% CO2 at 1–5 1 105/ml in RPMI
1640 media containing 100 U/ml penicillin, 100 mg/mlanalytical reverse-phase HPLC; these peptides were
judged to be 55–70% pure, depending on the length of streptomycin, and 20% heat-inactivated (567, 30 min) fetal
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TABLE 1
Reactivity in ELISA and Neutralization of SIVmac251 with Antisera Raised to Peptides
Containing Sequences of SIVmac251 to gp120 and gp36
Antibody titerb
Envelope
Peptide amino acids Sequencea ELISA Neutralization
SP-1 327–342 (C)MSGLVFHSQPLTDRPK 3,200 320
SP-1V 327–346 MSGLVFHSQPINDRPKQAWC 12,800 1024 (5832)
SP-2 313–331 CRRPGNKTVLPVTIMSGLV 50 0
SP-3 332–346 FHSQPLTDRPKQAWC 50 0
SP-4 313–346 CRRPGNKTVLPVTIMSGLVFHSQPLTDRPKQAW 25,600 20
SP-5A 327–362 MSGLVFHSQPLTDRPKQAWCWFGGKWKDAIKEVQT 3,200 0
SP-5 46–67 TKNRDTWGTTQCLPDNGDYSEL 12,800 0
SP-6 76–99 (C)DAWENTVTEQAIEDVWQLFETSIK 1,600 0
SP-7 111–131 MRCNKSETDRWGLTKSSTTIT 6,400 0
SP-8 137–153 SAPVSEKIDMVNETSSC 3,200 0
SP-9 176–196 GLKRDKTKEYNETWYSTDLVC 12,800 0
SP-10 196–213 CEQGNSTDNESRCYMNHC 25,600 0
SP-11 220–242 ESCDKHYWDTIRFRYCAPPGYAL 25,600 0
SP-12 265–289 CTRMMETQTSTWFGFNGTRAENRTY 50 0
SP-13 283–306 (C)RAENRTYIYWHGRDNRTIISLNKY 100 0
SP-14/15 349–372 (C)GGKWKDAIKEVKQTIVKHPRYTGT 800 0
SP-16 410–436 (C)LNWVEDRDVTTQRPKERHRRNYVPCHI 800 0
SP-17 434–460 CHIRQIINTWHKVGKNVYLPPREGDLT 3,200 0
SP-V5 468–490 LIANIDWTDGNQTSITMSAEVAE(CG) 50 0
SP-18 508–528 (C)GLAPTDVKRYTTGGTSRNKRG 800 0
DP-314 658–678 (C)EEAQIQQEKNMYELQKLNSWD 65,536 0
Antisera from macaques (N  7) infected with SIVmac251 ND 119, 372, 763, 2187, 2294, 7576,
8729 (cell viability assay)
a The V3 sequence of peptide SP-1 from Franchini et al. (1987) differs from that reported by Myers et al. (1993) at positions 337 and 338 (underlined)
of SIVmac251 gp120. Amino acids in parentheses have been added to facilitate coupling of peptide to carrier protein.
b Antibody titers shown for ELISA and neutralization assays are the highest levels achieved in one or more immunized animals. Peptides SP-4
and DP-314 were used to immunize guinea pigs (N  3) and C57BL/6 mice (N  6), respectively. All other peptides were used for immunization
of one or two goats. Neutralization is defined as ⁄90% inhibition of syncytium formation induced by SIVmac251 on CEMx174 cells. Neutralization
titer in parentheses: ⁄50% inhibition of cell killing by SIVmac251. 0, no neutralization. Antiserum to SP-1V also neutralized SIVDeltaB670 (50%
inhibition of cell killing  1/568) and SIVsmH4 (50% inhibition of cell killing  1/740). ND, not determined.
bovine serum that had been screened for mycoplasma a humidified chamber at 377 for 3–4 days. The number
contamination (Sigma Chemical Co.). SIVmac251 was of syncytia was then counted using an ocular grid. The
obtained from the NIH AIDS Research and Reference neutralizing titer was expressed as the reciprocal serum
Reagent Program operated by McKesson BioServices dilution that inhibited syncytium formation by 90% as esti-
Corp. Virus pools were prepared in CEMx174 cells, ti- mated by plotting the number of syncytia versus serum
tered for syncytia-forming units and infectious units as dilution. High-titered neutralizing antiserum from a rhe-
previously described (Langlois et al., 1991), and stored sus monkey infected with SIVmac251 was included in
in aliquots at 0707. each serum panel as a positive control. To demonstrate
specificity, neutralizing anti-peptide antibodies were ad-
Neutralization assays sorbed by incubating equal volumes of antisera with ei-
ther cognate or negative control peptides (1 mg/ml) forA syncytium inhibition assay for detecting antibodies
30 min at 237 prior to use in neutralization assays. Ad-that neutralized SIVmac251 was performed as previously
sorption of anti-peptide antisera was also performed indescribed (Langlois et al., 1991). Briefly, 30 ml of pooled
a similar manner with SIVmac239 gp130 and HIV-1IIIB/viral supernatants containing 100 syncytia-forming units
LAI gp120 (10–50 mg).was added to wells of a 96-well microtiter plate (Costar
Neutralizing antibodies to SIVmac251, SIVDeltaB670,half-area wells, Cat. No. 3696) containing 30 ml of twofold
and SIVsmH4 were also detected with a modified cellserial dilutions of heat-inactivated (567, 30 min) preim-
viability assay previously used to measure neutralizationmune or immune serum. After incubating the microtiter
of HIV-1 in MT-2 cells (Montefiori et al., 1988). For theplate at 377 for 30 min, HUT-78 or CEMx174 cells (31 103
in 30 ml) were added and plates were further incubated in assay, cell-free virus (50 ml containing 0.5–1 ng p27) was
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added to multiple dilutions of test sera (100 ml) in tripli- in buffer containing 50 mM carbonate buffer, pH 9.8, and
1 mM MgCl2 . Optical density readings were evaluatedcate wells of 96-well microdilution plates and incubated
at 377 for 30 min before adding CEMx174 cells (105 cells on a Titertek Multiskan II ELISA plate reader (Flow Labo-
ratories) at 405 nm. Samples were considered positivein 100 ml added per well). Cell densities were reduced
and media replaced after 3 days of incubation. Infection if the optical density reading was at least twofold higher
than the optical density reading obtained with preim-leads to extensive syncytium formation and virus-induced
cell killing in approximately 6 days when neutralizing mune or normal serum samples at the same dilution.
antibodies are not present. Neutralization was measured
by staining viable cells with Finter’s neutral red in poly- RESULTS
L-lysine-coated plates. Neutral red uptake by CEMx174
Neutralization of SIVmac251, SIV Delta B670, and
cells was linear from 3.1 1 104 to 5 1 105 viable cells/
SIVsmH4
well, corresponding to A540 values of 0.25 to 1.6. Percent-
age of protection was calculated by taking the difference Twenty-one peptides (Fig. 1, Table 1) containing hydro-
philic amino acid sequences of SIVmac251 gp120 andin absorption (A540 ) between test wells (cells / serum
sample / virus) and virus control wells (cells / virus) gp41/36 were synthesized, linked to either tetanus toxoid
or KLH, and used to immunize 36 goats, 12 guinea pigsand dividing by the difference in absorption between cell
control wells (cells only) and virus control wells. Assays [SP-1, 1V, 16 linked to KLH and cyclized SP-4 (no carrier)],
and six mice (DP-314–KLH). Antibody titers in ELISAwere harvested when virus-induced cell killing in virus
control wells was greater than 70% but less than 100%. against the immunizing peptide ranged from 1/50 to 1/
25,600 in goats (Table 1), 1/25,600 to 1/102,400 in guineaNeutralizing titers are given as the reciprocal of the
plasma dilution required to protect at least 50% of cells pigs (data not shown), and 1/32,768 to 1/65,536 in mice.
Antisera and preimmune sera were tested for the pres-from virus-induced killing. To evaluate the specificity of
neutralizing antibodies in the cell viability assay, anti- ence of neutralizing antibodies in two laboratories with
a syncytium inhibition assay [T.P., A.L.(anti-V3 antisera)]peptide antisera were preadsorbed with cognate or neg-
ative control peptides as described for the syncytium and also with a cell viability assay (D.M., anti-V3 anti-
sera). Only antisera raised to peptides containing se-inhibition assay.
quences of SIVmac251 V3 (aa 327–346) neutralized SIV-
mac251 (Table 1). Neutralizing titers in various goat seraEnzyme-linked immunosorbent assay
ranged from 1/20 to 1/1024 for 90% inhibition of syncy-
tium formation and 1/20 to 1/5832 in the cell viabilityEnzyme-linked immunosorbent assay (ELISA) was
used to measure anti-peptide antibody titers in sera from assay (50% inhibition of cell killing). Antisera to SP-1V
also neutralized SIVDeltaB670 and SIVsmH4 (50% inhibi-immunized and SIV-infected animals. For the assay, 50
ml of peptide or protein in CBC buffer (15 mM Na2CO3 , tion of cell killing at 1/568 and 1/740, respectively). For
comparison, neutralizing titers in sera from macaques35 mM NaHCO3 , pH 9.6) at a concentration of 40 mg/
well was added to wells of a 96-well microtiter plate chronically infected with SIVmac251 ranged from 1003 to
1005 in both inhibition of syncytium formation and cell(Costar 3590; Cambridge, MA) and incubated overnight
at 47. Wells were then emptied and incubated with 200 killing assays. Neutralizing antibodies were detected in
antisera raised to both V3 peptides SP-1 and SP-1V inml of blocking buffer (CBC buffer with 3% bovine serum
albumin and 0.1% sodium azide) at 237 for 2 hr and then which sequences vary at amino acids 337 and 338 (Table
1). Antisera raised in guinea pigs against cyclized andstored at 0207 until used. ELISA plates were washed
three times with ELISA wash buffer (0.15 M NaCl with linear V3 peptides contained lower levels of neutralizing
antibodies (1/20, data not shown) than those detected in0.05% Tween 20) at 200 ml/well prior to addition of serum
samples. Samples diluted in serum diluent [PBS, 0.05% sera from goats immunized with V3 peptides. Induction
of neutralizing antibodies in goats by immunization withTween 20, 5% normal goat serum, 5% (w/v) bovine serum
albumin] were added to ELISA wells (100 ml/well) and either SP-1V or SP-1 linked to KLH was highly variable
and required from 5 to 10 immunizations per animal. Ofincubated for 90 min at 237 or overnight at 47. Wells were
washed three times with ELISA wash buffer, 200 ml/well, 11 goats immunized with peptides containing sequences
of SIVmac251 V3, only 3 (Nos. 18, 125, and 246) producedfurther incubated for 60 min at 237 with 100 ml/well alka-
line phosphatase-conjugated antiserum to goat, guinea neutralizing antibody titers greater than 1/100. Collec-
tively, these data indicate that the linear neutralizing V3pig, or human IgG (Cappel, West Chester, PA) diluted 1/
7500 in serum dilution buffer lacking 5% goat serum. site within SIVmac251 gp120 V3 is weakly immunogenic
in both goats and guinea pigs. In addition, mabs BC11,ELISA microtiter plates were then washed three times
with wash buffer and then reacted for 45 min at 237 DC9, BB12, DF11, DA6, and FH12 raised to HIV-2 gp120
reacted strongly with SIV peptide SP-6 (aa 76–99) inwith 100 ml of the alkaline phosphatase substrate, p-
nitrophenyl phosphate (Sigma Chemical Co.) at 1 mg/ml ELISA but did not neutralize SIVmac251 (data not shown).
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FIG. 1. Synthetic peptides used in the study. Antisera raised in goats, guinea pigs, and mice to peptides SP-1, 1V, 2–18, V5, and DP-314 were
tested in ELISA and neutralization assays (Table 1). The peptide panel DP-146 to DP-176, RG-1, and RG-2 was used either to adsorb neutralizing
antisera or to map the binding sites of monoclonal antibodies raised to SIVmac251 or HIV-2 gp120. There is a premature stop codon in the env
gene encoding the gp32 transmembrane glycoprotein (break in solid bar). D, proteolytic cleavage site of gp160.
To evaluate the specificity of neutralizing anti-V3 anti- neutralizing antibodies to SIVDeltaB670 (preadsorption
neutralizing titer 1/568, postadsorption titer 1/10) andbodies, goat antisera to SP-1 and SP-1V (aa 327–346)
were adsorbed with peptides prior to testing in neutral- SIVsmH4 (preadsorption neutralizing titer 1/740, postad-
sorption titer 1/10), whereas adsorption with negativeization assays. Adsorption of anti-SP-1V antiserum 18
with either SP-1 or SP-1V abolished neutralization of SIV- control peptide SP-13 did not. To delineate more precisely
the linear neutralizing site within V3 of SIVmac251, we per-mac251 in both syncytium formation and cell viability
assays; whereas adsorption with equivalent amounts of formed adsorption experiments with truncated peptides
and with V3 peptides in which sequential alanine substitu-peptide SP-5 containing sequence outside of V3 had no
effect (Figs. 2A and 3). Adsorption with SIVmac239 gp130 tions were introduced into amino acids 329 to 339 (Fig. 4).
Peptides DP-150, -151, -152, and -153 containing SIV V3but not with HIV-1IIIB/LAI gp120 also removed all neu-
tralizing activity from goat 246 antiserum raised to SP- sequences within or including aa 331–339 did not adsorb
neutralizing anti-V3 antibodies raised to peptide SP-1V (aa1V (data not shown). Adsorption experiments were also
performed with peptides DP-146 (aa 337–346) and DP- 327–342). Neutralizing antibodies were also not adsorbed
by peptides DP-171 (aa 329–337) or DP-176 (aa 329–338).147 (aa 329–339) containing overlapping C-terminal or
N-terminal V3 sequences of SP-1V. Peptide DP-147 but However, peptide DP-154 (aa 329–339) completely ad-
sorbed neutralizing antibody activity in anti-SP-1V antiseranot DP-146 adsorbed neutralizing antibodies from anti-
SP-1V antisera in a dose-dependent manner when tested (Fig. 4). Adsorption of anti-SP-1V goat 246 antiserum with
peptides containing sequential alanine substitutions re-in syncytium inhibition assay (Figs. 2B and 3). These
results indicated the presence of a linear neutralizing vealed that replacement of amino acids F332, H333, S334, Q335,
P336, or D339 with alanine decreased the ability of peptidessite between aa 327–339.
With the cell viability neutralization assay, similar results to adsorb neutralizing anti-V3 antibodies by greater than
50%. Also, further mapping of the sites recognized by thewere obtained in that peptides SP-1, SP-1V, and DP-147
completely adsorbed neutralizing antibodies in goat anti- nonneutralizing mabs KK45 and KK46 to the V3 region of
SIVmac251 gp120 (Kent et al., 1991, 1992) indicated thatSP-1V antiserum 246 (Fig. 4). Adsorption of anti-SP-1V anti-
serum 246 with SP-1 or SP-1V also completely adsorbed these mabs bound to regions outside of the minimal neu-
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FIG. 2. Dose-dependent adsorption of neutralizing antibodies in goat 18 antiserum raised against peptide SP-1V (aa 327 – 346) containing
a V3 sequence of SIVmac251 gp120. Neutralizing goat anti-SP-1V antiserum was preadsorbed with varying amounts of SIVmac251 synthetic
peptides and then tested for the ability to inhibit SIVmac251-mediated syncytium formation. (A) Adsorption of anti-SP-1V antibodies with
peptide SP-1 (aa 327 – 346; Franchini et al., 1987) or SP-1V (aa 327 – 346; Myers et al., 1993) but not with SP-5 (aa 46 – 67). (B) Adsorption of
anti-SP-1V antibodies with peptide DP-147 (aa 327 – 339) but not with peptide DP-146 (aa 337 – 346) or SP-5 (aa 46 – 67). Results indicate the
presence of a V3 neutralizing site between aa 327 and 339 of SIVmac251 gp120. Data are representative of three to five experiments with
various V3 and non-V3 peptides.
FIG. 3. Adsorption of neutralizing anti-SP-1V goat 18 antiserum with peptides containing sequences of SIVmac251 gp120. Preadsorbed serum
was tested for the ability to inhibit SIVmac251-mediated syncytium formation. (A) Preimmune goat 18 serum, 1/10 dilution; (B) Anti-SP-1V antiserum
18, 1/160 dilution. Anti-SP-1V antiserum 18 adsorbed with (C) SP-1 (aa 327–346; Franchini et al., 1987), (D) SP-1V (aa 327–346; Myers et al., 1993),
(E) SP-5 (aa 46–67), (F) DP-146 (aa 337–346), (G) DP-147 (aa 327–339). (H) Rhesus anti-SIVmac251 antiserum, diluted 1/10. Results are representative
of three experiments.
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FIG. 4. Adsorption of goat 246 anti-SP-1V antiserum with peptides containing V3 sequences of SIVmac251 gp120 and with peptides A1–A11 in
which amino acids GLVFHSQPIND (aa 329–339) were sequentially replaced with alanine. After adsorption, antiserum was tested for the ability to
inhibit SIVmac251-mediated killing of CEMx174 human T-cells or for inhibition of syncytium formation (data for DP-171, 176, DP-151–154). Peptide
DP-154 contained the minimal neutralizing sequence (aa 329–339) within the V3 region of SIVmac251 gp120 (summarized in Table 2).
tralizing site (aa 329–339) defined in this study (Table 2). antibodies that bound strongly to DP-154 in ELISA (titer 1/
12800). Results allow the mapping of a minimal neutralizingIn ELISA, mabs KK45 and KK46 bound to both SP-1V and
DP-147 (aa 327–339) but not to DP-154 (aa 329–339) con- region of SIVmac251 to amino acids 329–339 (DP-154:
GLVFHSQPIND, aa 329–339) and further demonstrate thattaining the minimal linear neutralizing site (Table 2). In con-
trast, goat anti-SP-1V antisera 125 and 18 both neutralized mabs KK45 and KK46 binding to an epitope displaced by
2 amino acids from this neutralizing site (DP-147:SIVmac251 in syncytium inhibition assay and contained
TABLE 2
Adsorption/Peptide Binding of Anti-SIVmac251 V3 Polyclonal and Monoclonal Antibodies
Binding of monoclonal
Adsorption of antibodies
goat anti-SP-1V Amino acid
antiserum 246 KK45 KK46 Peptide number Sequence
/ / / SP-1 327–342 (C)MSGLVFHSQPLTDRPK
/ / / SP-1V 327–346 MSGLVFHSQPINDRPKQAWC
0 0 0 DP-146 337–346 INDRPKQAWC
/ { { DP-147 327–339 MSGLVFHSQPIND
/ 0 0 DP-154 329–339 GLVFHSQPIND
0 ND ND DP-153 331–339 VFHSQPIND
0 ND ND DP-152 332–339 FHSQPIND
0 ND ND DP-151 333–339 HSQPIND
0 ND ND DP-150 334–339 SQPIND
0 0 0 DP-171 329–337 GLVFHSQPI
0 0 0 DP-176 329–338 GLVFHSQPIN
ND 0 0 RG-1 329–340 GLVFHSQPINDR
ND 0 0 RG-2 329–341 GLVFHSQPINDRP
Note. ND, not determined; 0, 10% adsorption or binding relative to positive control peptide SP-1V; /, 90% adsorption or binding relative to
positive control peptide SP-1V; {, 25–50% binding relative to positive control peptide SP-1V. Mabs KK45 and KK46 from Kent et al. (1991, 1992).
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contained antibodies to DP-147 (aa 327–339) and none
of these sera contained antibodies to DP-154 (aa 329–
339), a peptide containing the minimal neutralizing re-
gion within V3. Moreover, DP-154 bound to ELISA microti-
ter wells as well as DP-147 and SP-1V as determined
with goat anti-SP-1V antisera 18 and 125 (not shown),
indicating that lack of rhesus antibody binding to DP-
154 was not due to differential peptide binding to ELISA
microtiter wells. Results are consistent with the hypothe-
sis that the minimal neutralizing site within V3 of SIV-
mac251 gp120 is weakly immunogenic in macaques in-
fected with SIVmac251.
FIG. 5. Antibody reactivity in ELISA to V3 peptides of SIVmac251 DISCUSSION
gp120 in sera (N 31) from rhesus macaques infected with SIVmac251.
Results are expressed as a ratio of mean optical density readings While linear V3 neutralizing regions of HIV-1 and HIV-
obtained from duplicate microtiter wells containing sera (1/50 dilution) 2 have been identified, homologous neutralizing sites
from SIVmac251-infected and uninfected macaques.
within the V3 domain of SIV gp120 have not. Moreover,
sequences within the V3 regions of HIV-1 and HIV-2 vary
throughout the course of infection (Zagury et al., 1988;MSGLVFHSQPIND, aa 327–339) does not result in neutral-
Holmes et al., 1992; Boeri et al., 1992) in contrast to theization of SIVmac251.
lack of genetic drift in SIV V3 (Almond et al., 1992, Burns
and Desrosiers, 1991; Johnson et al., 1991; OverbaughV3 peptides do not adsorb neutralizing antibodies
et al., 1991). Lack of variation within SIV V3 could indicateraised to recombinant or native SIV gp120
that immune responses to V3 do not provide sufficient
Antiserum to recombinant SIV 1A11 gp120 and anti- selective pressure in vivo to result in sequence variation.
sera from rhesus macaques infected with SIVmac251 However, it is also possible for retroviruses to evade
were adsorbed with V3 peptides SP-1 and SP-1V or non- immune surveillance by acquiring critical yet immunolog-
SIV peptide and then tested for neutralizing antibodies ically silent regions that are infrequently recognized as
against SIVmac251 in syncytium inhibition and cell killing foreign by the host (Beretta et al., 1987). Regions of ret-
assays. Following adsorption with an excess of V3 pep- roviral proteins that are weakly immunogenic or even
tides, there were no detectable decreases in neutralizing tolerogenic (Cianciolo et al., 1985; Golding et al., 1989;
antibody titers in either anti-SIV 1A11 gp120 antiserum Haynes et al., 1993) might allow escape from suppres-
(pre- and postadsorption titers of neutralizing antibodies sion of viral replication by immune effector responses
1/3200) or sera from SIVmac251-infected macaques (N and thereby contribute to viral pathogenesis. In the pres- 6) even though anti-V3 antibodies were detectable in ent study, we evaluated the immunogenicity of SIV-
anti-SIV 1A11 gp120 antiserum by ELISA and despite the mac251 V3 peptides in three animal species as well as
fact that recombinant SIV 1A11 gp120 can adsorb anti- the neutralizing activity of anti-V3 antibodies in an effort
SP-1V neutralizing antibodies (not shown). Data are con- to understand why linear V3 sequences of SIV gp120
sistent with the notion that other linear or conformational do not appear to evoke neutralizing antibody responses
sites comprise the immunodominant neutralizing regions despite sequence homology to neutralizing regions of
of SIV gp120. HIV-2 gp120.
Our study defined a linear neutralizing region of SIV-The minimal V3 neutralization site of SIVmac251 is
mac251 gp120 between amino acids 329 and 339 thatweakly immunogenic in macaques infected with
is weakly immunogenic both in immunized animals andSIVmac251
in macaques experimentally infected with SIVmac251
(Fig. 5). Of 11 goats and 9 guinea pigs immunized withSera from 31 rhesus macaques experimentally in-
fected with SIVmac251 were tested for antibodies to lin- peptides containing V3 sequences of SIVmac251 gp120,
only 3 goats produced neutralizing antibody responsesear determinants from the V3 region of SIVmac251 gp120
(Fig. 5). Twenty (65%) of these sera contained antibodies with titers greater than 1/100 in syncytium inhibition or
cell killing assays. However, neutralizing titers in thesethat reacted with peptide SP-4 containing the entire se-
quence of the V3 domain. Seven sera (23%) contained goat sera were substantial (1/1024 for 90% reduction of
syncytium formation or 1/5832 for 50% inhibition of cellantibodies reactive with peptide SP-1V (aa 327–346)
used in the present study to raise V3-specific neutralizing killing, Table 1), V3-specific (Figs. 2 and 3, Table 2), and
cross-neutralizing when tested against SIVDeltaB670antibodies to SIVmac251. However, only 4 sera (13%)
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and SIVsmH4. Moreover, of 54 antisera raised to various bound SP-1 [(C)MSGLVFHSQPLTDRPK, aa 327–342)],
SP-1V (MSGLVFHSQPINDRPKQAWC, aa 327–346), andSIV envelope peptides containing V3 and non-V3 se-
quences (Fig. 1, Table 1), we found that only V3 antisera DP-147 (MSGLVFHSQPIND, aa 327–339) in ELISA; how-
ever, neither mab bound DP-154 (GLVFHSQPIND, aaneutralized SIVmac251. Our results contrast with reports
of others (Robert-Guroff et al., 1992; Javaherian et al., 329–339) which can completely adsorb anti-SP-1V neu-
tralizing antibodies (Table 2, Figs. 2–4). In contrast, neu-1992) who were unable to demonstrate linear neutraliz-
ing sites within the V3 of SIV gp120. However, these tralizing goat 125 and 18 antisera to SP-1V bound
strongly to SP-1, SP-1V, DP-147, and DP-154 in ELISAnegative results could be due to the weak immunogenic-
ity of the linear V3 neutralizing site defined in our study. (titer against DP-154 1/12800). Collectively, our data map
a linear neutralizing site of SIVmac251 to the C-terminalLack of a detectable neutralizing antibody response to a
previously defined linear neutralizing site in V4 of SIV- region of gp120 V3 (aa 329–339) and define amino acids
F332, H333, S334, Q335, P336, and D339 as important recogni-mac251 (Torres et al., 1993) could be attributed to low
levels (1/800, Table 1) of anti-V4 antibodies generated in tion elements for neutralizing antibodies. A comparison
of HIV-2 and SIV V3 sequences from the Los Alamosgoats immunized with SP-16 (aa 410–436). We were not
able to demonstrate neutralizing antibodies to a pre- database (Myers et al., 1993) reveals that the central
FHSQP motif is highly conserved and thus might functionviously reported linear neutralizing site between aa 171
and 188 (Benichou et al., 1992) with antisera to SP-9 (aa as a neutralizing site for many HIV-2 and SIVmac/sm
isolates.176–196), possibly due to deletion of aa 171–175 from
the sequence of SP-9. Previous studies have shown that conformational sites
within a 46-kDa V3/V4 fragment between aa 249 and 505We performed adsorption experiments with SIV syn-
thetic peptides and recombinant SIVmac239 gp130 to constitute the PND of SIVmac251 gp120 (Javaherian et
al., 1992, 1994). This 46-kDa V3–V4 portion of SIVmac251evaluate the specificity of neutralizing antibodies raised
to SIV V3 peptides. Recombinant gp130, peptides SP-1 gp120 could adsorb the majority of neutralizing antibod-
ies in sera from guinea pigs immunized with gp120 or(aa 327–342; Franchini et al., 1987) and SP-1V (aa 327 –
346, Myers et al., 1992) could completely adsorb anti- in sera from macaques infected with SIVmac251,
whereas V3 peptides could not. In the present study, weSP-1V neutralizing antibodies (Figs. 2 and 3) despite se-
quence differences in peptides at aa 337 and 338 (SP- were also unable to adsorb neutralizing antibodies in
goat antiserum to SIV 1A11 gp130 or in sera from ma-1, LT; SP-1V, IN). Further adsorption experiments re-
vealed the presence of a minimal neutralizing region caques infected with SIVmac251. Thus, our results cor-
roborate previous studies regarding the conformationalwithin SIVmac251 envelope amino acids 329–339 (GLV-
FHSQPIND, DP-154) that has homology to one (peptide nature of the PND of SIVmac251. In contrast to the immu-
nogenicity of this conformational PND, we found that theA4-38, aa 311–330, SGRRFHSQKIINKKPRQAWC; Bjo¨rling
et al., 1991) of two linear neutralizing sites within the V3 linear C-terminal V3 neutralizing site between aa 329 and
339 is not recognized by antibodies in sera from any ofregion of HIV-2 gp120 (Bjo¨rling et al., 1994). Using pep-
tides in which amino acids were sequentially replaced 31 rhesus macaques infected with SIVmac251. Others
have also reported that the C-terminal region of SIVwith alanine, we identified amino acids F332, H333, S334,
Q335, P336, and D339 as being important for adsorption of gp120 V3 is weakly immunogenic in rhesus macaques
when compared to regions within or adjacent to the N-neutralizing antibody responses. These results are very
similar to those of Bjo¨rling et al. (1994) who identified terminus of V3 (Siegel et al., 1992; Benichou et al., 1993;
McBride et al., 1993; Sammuelsson et al., 1993; Torresthe homologous HIV-2 gp120 V3 amino acids F315, H316,
S317, Q318, and K319 as critical targets for antibody et al., 1993; Tanchou et al., 1995). Miller et al. (1992) have
also reported a low antigenic index prediction for thebinding in experiments with hyperimmune anti-HIV-2 V3
antisera and deletion sets of HIV-2 V3 peptides con- C-terminus of SIV V3. The observation that this linear
neutralizing site is poorly immunogenic and highly con-taining amino acids 311–330. In our study, but not in that
of Bjo¨rling et al. (1994), D339 appeared to be important served, in contrast to the highly immunogenic and vari-
able neutralizing V3 regions of HIV-1 and HIV-2, raisesfor binding of neutralizing antibodies, since either re-
placement of D339 with A or deletion of D339 from se- the possibility that SIV has evolved an alternate strategy
of escaping V3-directed immune surveillance other thanquences in peptides DP-171 (GLVFHSQPI, aa 329–337)
or DP-176 (GLVFHSQPIN, aa 329–338) abrogated the antigenic variation. This strategy would involve the incor-
poration of V3 neutralizing sequences that are poorlyability of these peptides to adsorb neutralizing anti-V3
antibodies (Table 2, Fig. 4). The requirement for neutraliz- immunogenic and therefore resistant to immune selec-
tive pressure. This process of immune evasion could being antibodies to recognize SIV V3 aa 329–339 (DP-154,
GLVFHSQPIND) was further highlighted by mapping facilitated by the adoption of V3 neutralizing sequences
either that are homologous to those of the host (Reiherstudies performed with nonneutralizing mabs KK45 and
KK46 against the V3 domain of SIVmac251. Both mabs et al., 1986; Berreta et al., 1987) or that are directly tolero-
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protein of simian immunodeficiency virus. AIDS Res. Hum. Retrovi-genic (Cianciolo et al., 1985; Haynes et al., 1993). Addi-
ruses 8, 1165–1170.tional analysis of cellular and immune responses to the
Benichou, S., Venet, A., Beyer, C., Tiollais, P., and Madaule, P. (1993).
linear neutralizing V3 site defined in this study is needed Characterization of B-cell epitopes in the envelope glycoproteins of
to evaluate this hypothesis. simian immunodeficiency virus. Virology 194, 870–874.
Beretta, A., Grassi, F., Pelagi, M., Clivio, A., Parravicini, C., Giovinazzo,Difficulties in generating neutralizing anti-V3 antibod-
G., Andronico, F., Lopalco, L., Verani, P., Butto`, S., Titti, F., Rossi,ies to SIV are reminiscent of those associated with the
G. B., Viale, G., Ginelli, E., and Siccardi, A. G. (1987). HIV env glycopro-resistance of HIV-1 primary isolates to V3-targeted neu-
tein shares a cross-reacting epitope with a surface protein present
tralization. Moore et al. (1995) have shown that HIV-1 on activated human monocytes and involved in antigen presentation.
primary isolates are insensitive to neutralization by V3- Eur. J. Immunol. 17, 1793–1798.
Bjo¨rling, E., Broliden, K., Bernardi, D., Utter, G., Thorstensson, R., Choidi,specific antibodies which neutralize prototypic strains.
F., and Norrby, E. (1991). Hyperimmune antisera against syntheticIn addition, VanCott et al. (1995) recently reported that
peptides representing the glycoprotein of human immunodeficiencyantibody depletion with autologous V3 peptides had little
virus type 2 can mediate neutralization and antibody-dependent cyto-
effect on primary isolate neutralization by sera from in- toxic activity. Proc. Natl. Acad. Sci. USA 88, 6082–6086.
fected individuals. Others have shown that HIV-1 con- Bjo¨rling, E., Chiodi, F., Utter, G., and Norrby, E. (1994). Two neutralizing
domains in the V3 region in the envelope glycoprotein gp125 of HIVtains neutralizing epitopes in the V3 loop (Bou-Habib et
type 2. J. Immunol. 152, 1952–1959.al., 1994) and other regions of gp120 (Broder et al., 1994;
Boeri, E., Giri, A., Lillo, F., Ferari, G., Varnier, O. E., Ferro, A., Sabbatani,Sullivan et al., 1995) that are poorly exposed on native
S., Saxinger, W. C., and Franchini, G. (1992). In vivo genetic variability
virus particles. In a similar manner, difficulties in neu- of the human immunodeficiency virus type 2 V3 region. J. Virol. 66,
tralizing SIV with anti-V3 antibodies could also be related 4546–4550.
Bou-Habib, D. C., Roderiquez, G., Oravecz, T., Berman, P. W., Lusso,to problems of antibody recognition of V3 on the surface
P., and Norcross, M. A. (1994). Cryptic nature of envelope V3 regionof the virion if, for instance, most of V3 were inaccessible
epitopes protects primary monocytotropic human immunodeficiencyto antibody binding except for the linear neutralizing site
virus type 1 from antibody neutralization. J. Virol. 68, 6006–6013.
between aa 329 and 339. Our results are also consistent Broder, C. C., Earl, P. L., Long, D., Abedon, S. T., Moss, B., and Doms,
with this hypothesis and imply that SIV and HIV-1 primary R. W. (1994). Antigenic implications of human immunodeficiency virus
type 1 envelope quaternary structure: Oligomer-specific and -sensi-isolates could share similar neutralizing characteristics.
tive monoclonal antibodies. Proc. Natl. Acad. Sci. USA 91, 11699–In summary, we have identified a linear, conserved
11703.neutralizing site of SIVmac251 gp120 V3 that is homolo-
Burns, D. P. W., and Desrosiers, R. C. (1991). Selection of genetic
gous to a previously reported neutralizing region of HIV- variants of simian immunodeficiency virus in persistently infected
2 gp120. This neutralizing site is weakly immunogenic in rhesus monkeys. J. Virol. 65, 1843–1854.
Campbell, B. J., and Hirsch, V. M. (1994). Extensive envelope heteroge-rhesus macaques, goats, and guinea pigs, which likely
neity of simian immunodeficiency virus in tissues from infected ma-precludes its use in vaccine strategies against SIV. Lack
caques. J. Virol. 68, 3129–3137.of sequence variability and poor immunogenicity within
Cann, A. J., Churcher, M. J., Boyd, M., O’Brien, W., Zhao, J.-Q., Zack, J.,
this V3 neutralizing region could indicate that SIV evades and Chen, I. S. Y. (1992). The region of the envelope gene of human
V3-directed immune surveillance by incorporating se- immunodeficiency virus type 1 responsible for determination of cell
tropism. J. Virol. 66, 305–309.quences that are ‘‘self-like’’ or tolerogenic.
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